Roth Capital set a $158.00 price target on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) in a report released on Monday. The brokerage currently has a buy rating on the biotechnology company’s stock.

Other equities analysts have also recently issued reports about the company. Stephens reissued an overweight rating and set a $137.00 price objective (up from $125.00) on shares of Ligand Pharmaceuticals in a report on Wednesday, August 9th. BidaskClub cut Ligand Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Wednesday, July 19th. Deutsche Bank AG reaffirmed a hold rating and issued a $103.00 price target (up from $100.00) on shares of Ligand Pharmaceuticals in a research note on Monday, July 17th. TheStreet raised Ligand Pharmaceuticals from a c rating to a b- rating in a research note on Monday, August 7th. Finally, HC Wainwright reaffirmed a buy rating and issued a $150.00 price target on shares of Ligand Pharmaceuticals in a research note on Tuesday, September 5th. Three research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of Buy and an average target price of $144.20.

Shares of Ligand Pharmaceuticals (NASDAQ:LGND) traded up $2.90 during midday trading on Monday, hitting $142.80. The company had a trading volume of 291,300 shares, compared to its average volume of 247,139. The stock has a market cap of $2,970.00, a PE ratio of 105.19, a price-to-earnings-growth ratio of 2.16 and a beta of 0.93. The company has a current ratio of 0.97, a quick ratio of 0.95 and a debt-to-equity ratio of 0.05. Ligand Pharmaceuticals has a 52 week low of $95.08 and a 52 week high of $149.31.

Ligand Pharmaceuticals (NASDAQ:LGND) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported $0.69 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.37 by $0.32. The company had revenue of $33.38 million for the quarter, compared to analysts’ expectations of $31.04 million. Ligand Pharmaceuticals had a return on equity of 7.83% and a net margin of 12.76%. Ligand Pharmaceuticals’s revenue for the quarter was up 54.4% compared to the same quarter last year. During the same period last year, the firm posted $0.62 EPS. sell-side analysts anticipate that Ligand Pharmaceuticals will post 2.35 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Ligand Pharmaceuticals Incorporated (LGND) Given a $158.00 Price Target at Roth Capital” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/ligand-pharmaceuticals-incorporated-lgnd-given-a-158-00-price-target-at-roth-capital/1703192.html.

In other news, CEO John L. Higgins sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $130.00, for a total transaction of $650,000.00. Following the transaction, the chief executive officer now directly owns 144,171 shares of the company’s stock, valued at $18,742,230. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jason Aryeh sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $127.99, for a total value of $255,980.00. Following the transaction, the director now directly owns 59,625 shares in the company, valued at $7,631,403.75. The disclosure for this sale can be found here. 14.70% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. First Republic Investment Management Inc. increased its stake in shares of Ligand Pharmaceuticals by 8.9% during the third quarter. First Republic Investment Management Inc. now owns 5,793 shares of the biotechnology company’s stock valued at $789,000 after buying an additional 471 shares during the period. Envestnet Asset Management Inc. increased its stake in shares of Ligand Pharmaceuticals by 13.8% during the third quarter. Envestnet Asset Management Inc. now owns 6,655 shares of the biotechnology company’s stock valued at $905,000 after buying an additional 808 shares during the period. Convergence Investment Partners LLC purchased a new position in shares of Ligand Pharmaceuticals during the third quarter valued at approximately $1,838,000. Cornerstone Capital Inc. increased its stake in shares of Ligand Pharmaceuticals by 5.5% during the third quarter. Cornerstone Capital Inc. now owns 71,413 shares of the biotechnology company’s stock valued at $9,723,000 after buying an additional 3,744 shares during the period. Finally, Stifel Financial Corp increased its stake in shares of Ligand Pharmaceuticals by 1,447.2% during the third quarter. Stifel Financial Corp now owns 109,124 shares of the biotechnology company’s stock valued at $14,839,000 after buying an additional 102,071 shares during the period.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.

Receive News & Ratings for Ligand Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.